Arrow Financial Corp Has $57,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

Arrow Financial Corp trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 29.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 235 shares of the medical instruments supplier’s stock after selling 100 shares during the quarter. Arrow Financial Corp’s holdings in Becton, Dickinson and Company were worth $57,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Livelsberger Financial Advisory acquired a new position in Becton, Dickinson and Company during the third quarter worth $26,000. Tompkins Financial Corp increased its position in shares of Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares in the last quarter. Sound Income Strategies LLC raised its holdings in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the last quarter. Opal Wealth Advisors LLC bought a new position in Becton, Dickinson and Company in the 2nd quarter valued at about $45,000. Finally, Abound Wealth Management boosted its stake in Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Up 2.0 %

NYSE BDX opened at $231.64 on Monday. The stock has a market capitalization of $66.95 billion, a price-to-earnings ratio of 47.66, a PEG ratio of 1.80 and a beta of 0.43. The business’s fifty day moving average is $237.04 and its 200-day moving average is $235.09. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the company earned $3.42 earnings per share. The company’s quarterly revenue was up 6.9% on a year-over-year basis. Equities research analysts predict that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a $1.04 dividend. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.80%. The ex-dividend date of this dividend is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 78.19%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on BDX. Raymond James lowered their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI lifted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Stifel Nicolaus boosted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.